FDA Adverse Event Injury Summary report: N

REZUM

MDR report key: 19560545 · Received June 18, 2024

Report

Report Number
2124215-2024-36913
Event Type
Injury
Date Received
June 18, 2024
Date of Event
May 30, 2024
Report Date
July 1, 2024
Manufacturer
BOSTON SCIENTIFIC CORPORATION
Product Code
KNS
Adverse Event
Yes
Report Source
Manufacturer report
Reporter Location
SA
Reporter Occupation
PHYSICIAN
Health Professional
Yes

Narratives

Additional Manufacturer Narrative · 0

ALAMRI N A, EID K, ALSHEHRI M (DECEMBER 05, 2023) DEVELOPMENT OF A PROSTATIC URETHRAL CYST AFTER REZUM CAUSING PERSISTENT LOWER URINARY TRACT SYMPTOMS. CUREUS 15(12): E49969. DOI 10.7759/CUREUS.49969. CORRECTION TO FIELD H6. PATIENT CODES. WITH ALL THE AVAILABLE INFORMATION, BOSTON SCIENTIFIC CONCLUDES THAT REPORTED COMPLAINT COULD NOT BE CONFIRMED, DUE TO THE DEVICE DID NOT RETURN. THERE WAS NO DEVICE AVAILABLE FOR ANALYSIS AND THERE WAS NO REPORT OF A DEVICE PERFORMANCE ALLEGATION DURING TREATMENT. THE PATIENT SYMPTOMS OF DYSURIA, URINARY URGENCY AND INFLAMMATION ARE A KNOWN INHERENT RISK OF DEVICE USE AS STATED IN THE INSTRUCTIONS FOR USE. BASED ON ALL THE INFORMATION AVAILABLE, KNOWN INHERENT RISK OF DEVICE WAS THE CONCLUSION CODE ASSIGNED TO THIS INVESTIGATION.

Additional Manufacturer Narrative · 0

ALAMRI N A, EID K, ALSHEHRI M (DECEMBER 05, 2023) DEVELOPMENT OF A PROSTATIC URETHRAL CYST AFTER REZUM CAUSING PERSISTENT LOWER URINARY TRACT SYMPTOMS. CUREUS 15(12): E49969. DOI 10.7759/CUREUS.49969.

Description of Event or Problem · 0

IT WAS REPORTED THAT A LITERATURE ARTICLE PUBLISHED IN CUREUS, THAT A CASE STUDY WAS CONDUCTED IN THE CASE OF A 71-YEAR-OLD MALE PATIENT WHO WAS TREATED WITH A WATER VAPOR THERAPY PROCEDURE. THE PATIENT PRESENTED WITH A HISTORY OF DIABETES, HYPERLIPIDEMIA, AND PROSTATIC ENLARGEMENT AND WAS ON ALFUZOSIN. ADDITIONALLY, THE PATIENT COMPLAINED OF URGENCY AND FREQUENCY, WHICH DID NOT IMPROVE AFTER USING SOLIFENACIN. THE PATIENT WAS TREATED WITH WATER VAPOR THERAPY AND BY THE POST-OPERATIVE FOLLOW-UP, THE SYMPTOMS IMPROVED. HOWEVER, FIVE MONTHS AFTER THE TREATMENT, THE PATIENT PRESENTED WITH DYSURIA AND URGENCY. THEREFORE, AN ULTRASOUND WAS PERFORMED TO EVALUATE THE PERSISTENT LOWER URINARY TRACT SYMPTOMS, AND DUE TO THAT, IT WAS IDENTIFIED THAT THE PATIENT DEVELOPED A PROSTATIC URETHRAL CYST. THE DISCOVERED LESION WAS TREATED WITH A CONSERVATIVE TREATMENT APPROACH DUE TO THE DECISION OF THE PATIENT.

Description of Event or Problem · 0

IT WAS REPORTED THAT A LITERATURE ARTICLE PUBLISHED IN CUREUS, THAT A CASE STUDY WAS CONDUCTED IN THE CASE OF A 71-YEAR-OLD MALE PATIENT WHO WAS TREATED WITH A WATER VAPOR THERAPY PROCEDURE. THE PATIENT PRESENTED WITH A HISTORY OF DIABETES, HYPERLIPIDEMIA, AND PROSTATIC ENLARGEMENT AND WAS ON ALFUZOSIN. ADDITIONALLY, THE PATIENT COMPLAINED OF URGENCY AND FREQUENCY, WHICH DID NOT IMPROVE AFTER USING SOLIFENACIN. THE PATIENT WAS TREATED WITH WATER VAPOR THERAPY AND BY THE POST-OPERATIVE FOLLOW-UP, THE SYMPTOMS IMPROVED. HOWEVER, FIVE MONTHS AFTER THE TREATMENT, THE PATIENT PRESENTED WITH DYSURIA AND URGENCY. THEREFORE, AN ULTRASOUND WAS PERFORMED TO EVALUATE THE PERSISTENT LOWER URINARY TRACT SYMPTOMS, AND DUE TO THAT, IT WAS IDENTIFIED THAT THE PATIENT DEVELOPED A PROSTATIC URETHRAL CYST. THE DISCOVERED LESION WAS TREATED WITH A CONSERVATIVE TREATMENT APPROACH DUE TO THE DECISION OF THE PATIENT.

Devices

Seq Brand Generic Product Code Manufacturer Model Lot UDI-DI
2315529 REZUM UNIT, ELECTROSURGICAL ENDOSCOPIC (WITH OR WITHOUT ACCESSORIES) KNS BOSTON SCIENTIFIC CORPORATION

Patients

Seq Age Sex Outcome Treatment
1 71 YR Male Other